BRAF p.V600K
About
Gene context: BRAF
Biomarker Type: Somatic Variant
Present: True
Chromosome: 7
Start Position: 140453136
End Position: 140453137
Reference Allele: AC
Alternate Allele: TT
Cdna Change: c.1798_1799GT>AA
Protein Change: p.V600K
Variant Annotation: Missense
Exon: 15
Rsid: rs121913227
Hgvsg: 7:g.140453136_140453137delinsTT
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| EMA (2) FDA (2) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (4) FDA (4) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Trametinib | |
| FDA (1) | BRAF p.V600K | Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease | Vemurafenib | |
| FDA (1) | BRAF p.V600K | Low-Grade Glioma, NOS | Tovorafenib | |
| EMA (2) | BRAF p.V600K | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| EMA (1) | BRAF p.V600K | Melanoma | Dabrafenib | |
| EMA (1) | BRAF p.V600K | Melanoma | Vemurafenib |